[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nephrectomy--methods\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nephrectomy--methods":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,76,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053280","phase-3-reck-vs-exparel-in-robotic-nephrectomy-100053280",false,"NCT07092566","R.E.C.K vs Exparel in Robotic Nephrectomy","Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial","Inclusion Criteria:\n\n1. Ability to understand and willingness to sign an IRB-approved informed consent\n2. Age ≥ 18 years at the time of consent.\n3. Planned robotic partial or radical nephrectomy\n\nExclusion Criteria:\n\n1. Determined not to be a candidate to receive R.E.C.K or Exparel per the enrolling investigator\n2. Known pregnancy\n3. Chronic opioid use within 30 days (as per patient report) prior to randomization (defined as ≥ 30 MME\u002Fday)\n4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements as determined by the investigator.\n5. Known allergy to R.E.C.K. and\u002For Exparel","ALL","18 Years",{"count":19,"type":20},170,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.",[26,27,28],"Renal Carcinoma","Nephrectomy \u002F Methods","Pain Management",[30,31],"Analgesics","Nephrectomy","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2025-11-14",{"date":40,"type":20},"2027-10",{"name":42,"class":43},"Wake Forest University Health Sciences","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100635864","multimodal-anesthesia-in-robotic-laparoscopic-nephrectomy-100635864","NCT07558226","Multimodal Anesthesia in Robotic Laparoscopic Nephrectomy","Efficacy of Multimodal Anesthesia in Robotic Laparoscopic Nephrectomy: Impact on Recovery and Early Hospital Discharge.","MANTRA","Inclusion Criteria:\n\n* Patients ≥18 years.\n* Indication for elective oncological robotic partial or radical nephrectomy.\n* ASA classification I-III.\n* Candidates for short-stay surgery according to institutional protocol.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Chronic opioid use. Defined as continuous opioid use during the 3 months prior to surgery\n* Uncontrolled chronic pain. Defined as chronic pain not adequately controlled with usual treatment during the 3 months prior to surgery.\n* Contraindications to NSAIDs, regional anesthesia, or drugs of the multimodal protocol.\n* Advanced renal failure (GFR \\\u003C30 ml\u002Fmin) at the preanesthetic visit.",{"count":54,"type":20},80,[56],"NA","It is a prospective, randomized, controlled and superiority clinical trial, with the objective of comparing the effectiveness of multimodal anesthesia versus conventional anesthesia in patients undergoing oncological robotic nephrectomy within a short-stay surgery program (SSA). The effect of no specific drug will be evaluated, but rather the anesthetic approach ologies of surgical patients. The clinical trial will be carried out in a third-level university hospital, between the first half of 2026 and the second half of 2027 and, after approval by the corresponding Clinical Research Ethics Committee.",[59,60,27],"Anesthesia","Anesthesia and Procedure Related Time Intervals",[62,63,64,59,65,31,66],"laparoscopic nephrectomy robotic","multimodal anesthesia","early hospital discharge","Multimodal","Robotic","2026-06-29",{"date":69,"type":36},"2026-07-01",{"date":71,"type":36},"2026-05-02",{"date":73,"type":20},"2027-11-30",{"name":75,"class":43},"Fundacio Puigvert",{"id":77,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":24,"conditions":80,"keywords":81,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":87,"locationsCount":44},"100600059",{"count":19,"type":20},[23],[26,27,28],[30,31],"2026-01-16",{"date":84,"type":36},"2026-01-20",{"date":38,"type":36},{"date":40,"type":20},{"name":42,"class":43},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":118,"locationsCount":44},"100571189","a-study-of-3d-visualization-techniques-to-improve-the-quality-and-safety-of-robot-assisted-nephron-sparing-surgery-for-complex-renal-tumors-100571189","NCT06717009","A Study of 3D Visualization Techniques to Improve the Quality and Safety of Robot-assisted Nephron Sparing Surgery for Complex Renal Tumors.","A Prospective, Multicenter, Randomized Controlled Study of Three-dimensional Visualization Techniques to Improve the Quality and Safety of Robot-assisted Nephron Sparing Surgery for Complex Renal Tumors","Inclusion Criteria:\n\n1. The imaging diagnosis is single renal cell carcinoma, clinical stage is T1N0M0-T2N0M0, and the contralateral kidney function is good.\n2. Physical status and organ function allow robotic-assisted partial nephrectomy.\n3. Be able to adhere to the protocol during the study.\n4. The age ranges from 18 to 75 years, and there is no chronic kidney disease.\n5. KPS \\> 80; ECOG score: 0-1; There are no other serious concomitant diseases and the organ function is good.\n6. There are no medical contraindications seriously affecting anesthesia and surgery.\n7. The patient has no history of other malignant tumors in the past 5 years.\n8. There is no surgical history of epigastrium and the affected kidney.\n9. Estimated survival is more than 6 months, and there are no other severe diseases that reduce survival to less than 5 years.\n\nExclusion Criteria:\n\n1. Women who are pregnant or lactating, or who are of reproductive age and are not using effective contraception.\n2. Comorbid serious medical diseases or conditions, for example, clinically severe or active heart disease, severe uncontrolled medical illnesses and infections, severe uncontrolled digestive disorder, severe electrolyte disturbance, active disseminated intravascular coagulation, major organ failure such as decompensated cardiac, pulmonary, hepatic, or renal failure, symptomatic peripheral neuropathy. Can not tolerate robot-assisted laparoscopic partial nephrectomy\n3. Organ transplant recipients requiring immunosuppressive therapy.\n4. There is history of other malignancies within 5 years of trial initiation, excluding cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.\n5. Patients who have received biological therapy or other anticancer traditional Chinese medicine within 4 weeks.\n6. Patients with multiple or bilateral renal tumors or solitary renal tumors.\n7. Patient without complete clinical information.","75 Years",{"count":97,"type":20},350,[56],"The goal of this clinical trial is to learn the evidence-based medical value of 3D visualization techniques to improve tumor control, preservation of renal function, and perioperative safety in robot-assisted nephron sparing surgery for complex renal tumors. The main question it aims to answer is:\n\nIs 3D visualization techniques more effective in improving robot-assisted nephron sparing surgery for complex renal tumors in terms of tumor control, renal function preservation, and perioperative safety.\n\nThe researchers will randomize participants into a 3D trial group and a conventional group for comparison.\n\nParticipants will:\n\nComplete Blood routine, liver and kidney function tests on the first and third day after operation.\n\nHave Renography at 3 and 12 months after the operation. Cooperate with follow-up visits.",[101,102,103,27],"Kidney Neoplasms \u002F Surgery","Robotic Surgical Procedures","Imaging, Three-Dimensional \u002F Methods",[105,106,107,108,109,110],"Three-dimensional visualization technique;","Three-dimensional reconstruction","Robotic surgery","Kidney neoplasms","Laparoscopy","Nephron sparing surgery","NOT_YET_RECRUITING","2024-11-29",{"date":114,"type":36},"2024-12-04",{"date":116,"type":20},"2025-01",{"date":40,"type":20},{"name":119,"class":43},"Tianjin Medical University Cancer Institute and Hospital"]